Press Release
<< Back
Verastem to Present at Upcoming Scientific Conferences
-Results from a Phase 1 study of VS-6063 in Japanese patients to be announced-
• |
12th International Congress on Targeted Anticancer Therapies on Wednesday, March 5, 2014 at the Capitol Hilton in Washington, D.C. |
|
Abstract Title: Addressing the Drug Lag in Japan: A Phase 1 Study of Defactinib in Japanese Subjects to Facilitate Multiregional Clinical Trials |
||
Abstract Code: P6.1 |
||
Date and Time: Wednesday, March 5 at 6 PM, during Welcome Reception & Posterviewing |
||
Session: P6 |
||
• |
4th International Conference on Tumor Progression and Therapeutic Resistance on Monday, March 10, 2014 at the Omni Parker Hotel in Boston, MA |
|
Presentation Title: Cancer Stem Cells as Potential Sources of Therapeutic Resistance |
||
Presenter: Robert Weinberg, Ph.D., Professor, Massachusetts Institute of Technology, Whitehead Institute of Biomedical Research and Verastem co-founder and Chair of Scientific Advisory Board |
||
Date and Time: Monday, March 10 at 10:15 AM |
||
Session: 2 |
||
Session Title: Cancer Stem Cells/Tumor Heterogeneity |
||
Presentation Title: Development of Small Molecule Inhibitors of FAK and P13K/mTOR that Preferentially Target Cancer Stem Cells |
||
Presenter: Jonathan Pachter, Ph.D., Verastem Head of Research |
||
Date and Time: Monday, March 10 at 5:00 PM |
||
Session: 4 |
||
Session Title: Personalized/Targeted Therapeutics |
||
About VS-6063
VS-6063 is an orally available compound designed to target cancer stem
cells through the potent inhibition of focal adhesion kinase (FAK).
Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research by
About
Forward-looking statements:
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com